Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives $54.20 Consensus Price Target from Analysts

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) have earned an average recommendation of “Buy” from the seven analysts that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $54.20.

TARS has been the subject of a number of recent research reports. William Blair raised shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. The Goldman Sachs Group boosted their price objective on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a report on Friday, November 15th. Finally, Oppenheimer increased their target price on shares of Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the stock an “outperform” rating in a research report on Thursday, November 14th.

Tarsus Pharmaceuticals Stock Performance

TARS opened at $52.45 on Friday. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. The company has a market capitalization of $2.01 billion, a PE ratio of -13.77 and a beta of 1.00. The business has a fifty day simple moving average of $41.05 and a 200 day simple moving average of $33.34. Tarsus Pharmaceuticals has a 1 year low of $15.60 and a 1 year high of $52.99.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Franklin Resources Inc. boosted its holdings in shares of Tarsus Pharmaceuticals by 9.3% in the 3rd quarter. Franklin Resources Inc. now owns 12,164 shares of the company’s stock valued at $444,000 after purchasing an additional 1,033 shares in the last quarter. Geode Capital Management LLC boosted its stake in Tarsus Pharmaceuticals by 8.1% in the third quarter. Geode Capital Management LLC now owns 835,790 shares of the company’s stock valued at $27,494,000 after buying an additional 62,555 shares in the last quarter. Barclays PLC boosted its stake in Tarsus Pharmaceuticals by 345.9% in the third quarter. Barclays PLC now owns 98,663 shares of the company’s stock valued at $3,246,000 after buying an additional 76,538 shares in the last quarter. Wellington Management Group LLP grew its position in Tarsus Pharmaceuticals by 14.2% in the third quarter. Wellington Management Group LLP now owns 145,347 shares of the company’s stock valued at $4,780,000 after acquiring an additional 18,019 shares during the last quarter. Finally, Ikarian Capital LLC raised its stake in Tarsus Pharmaceuticals by 28.7% during the third quarter. Ikarian Capital LLC now owns 1,030,277 shares of the company’s stock worth $33,886,000 after acquiring an additional 230,000 shares in the last quarter. 90.01% of the stock is currently owned by institutional investors and hedge funds.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.